Endocrine Abstracts

PSMA-11 belongs to the substance class of peptidomimetic prostate-specific membrane antigen (PSMA) inhibitors. In general, the class of urea-based PSMA inhibitors was firstly described by Kozikowski et al. in 2001 [1] and one of the first preclinical imaging studies using PSMA radioligands in PSMA-positive tumor xenografts were reported by Pomper et al. in 2005 [2]. PSMA is an optimal target both for imaging and therapy of prostate cancer. The now well establ...